pretreatment with eipa (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
97
Structured Review
MedChemExpress
pretreatment with eipa
Pretreatment With Eipa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 149 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eipa/EIPA/pm42834177-535-25-30
Average 97 stars, based on 149 article reviews
Pretreatment With Eipa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 149 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eipa/EIPA/pm42834177-535-25-30
Average 97 stars, based on 149 article reviews
pretreatment with eipa - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Recombinant:Article Title: Engineered Lysosome-Targeted Protein Degradation via Hijacking Macropinocytosis. Article Snippet: Recently, targeted protein degradation (TPD) strategies have emerged as an effective tool for addressing undruggable targets in both biomedical research and the pharmaceutical industry, selectively binding proteins of interest and targeting them to the intracellular degradation machinery for degradation.. However, the targeting of extracellular proteins with current degradation tools requires a tedious, case-specific selection and design process based on lysosomal trafficking of cell surface receptors.. Here, we introduce Macropinocytosis-Targeting Chimeras (MapTACs), a TPD platform that exploits macropinocytosis, a receptor-independent endocytic process, to deliver extracellular proteins to lysosomes for degradation. Inhibition:Article Title: TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia. Article Snippet: Acute myeloid leukemia (AML) remains challenging, especially for older or unfit individuals who develop resistance to venetoclax (VEN)-based regimens.. Although TIM3 represents a promising AML target, clinical blockade has yielded suboptimal outcomes.. Here, we develop VINCENT (VEN-integrated natural killer cell engager targeting TIM3), a therapeutic platform combining anti-CD16 and anti-TIM3 antibodies with nanoformulated VEN. Injection:Article Title: TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia. Article Snippet: Acute myeloid leukemia (AML) remains challenging, especially for older or unfit individuals who develop resistance to venetoclax (VEN)-based regimens.. Although TIM3 represents a promising AML target, clinical blockade has yielded suboptimal outcomes.. Here, we develop VINCENT (VEN-integrated natural killer cell engager targeting TIM3), a therapeutic platform combining anti-CD16 and anti-TIM3 antibodies with nanoformulated VEN. |